Eisai To Shut Down H3 In Global R&D Restructuring
New Structure From October; New Astellas W Coast Campus
Eisai has decided to shut down its US oncology research operation H3 by September in the course of restructuring its global R&D organization. The majority of H3 employees will be laid off as Eisai Inc. and new organization DHBL absorb its functions and assets. Meanwhile another Japanese pharma firm, Astellas, builds up its US R&D footprint.
You may also be interested in...
Japan's top pharma firms logged generally strong performances for mainstay global drugs in the fiscal period ended 30 September, with the weakened yen adding substantially to figures for those with large overseas sales. Astellas and Eisai are among those awaiting important global-first approvals for potential blockbusters.
Kyorin Pharma is to end operations at its US subsidiary ActivX 18 years since its acquisition. Although the California firm’s kinase-probing technology has contributed to Kyorin’s R&D, the Japanese firm acknowledged limits to future applicability in the development of candidate compounds.
In this week's podcast version of Five Must-Know Things: BMS’s new products meet early expectations; Eisai to shut a US unit in global R&D restructuring; Roche aims high for Vabysmo; US priority review for Biogen’s ALS contender; and a chat with Gennova’s CEO.